Cargando…

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis

Heart failure with preserved ejection fraction (HFpEF) currently accounts for approximately half of all new heart failure cases in the community. HFpEF is closely associated with chronic lifestyle-related diseases, such as obesity and type 2 diabetes, and clinical outcomes are worse in those with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilak, Joanna M, Alam, Uazman, Miller, Christopher A, McCann, Gerry P, Arnold, Jayanth R, Kanagala, Prathap
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2022
Materias:	Patients with HFpEF
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274364/ https://www.ncbi.nlm.nih.gov/pubmed/35846985 http://dx.doi.org/10.15420/cfr.2022.12

Ejemplares similares

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Fukuta, Hidekatsu
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure
por: Packer, Milton
Publicado: (2021)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
por: Oduah, Mary-Tiffany, et al.
Publicado: (2023)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2015)

Plasma P‐selectin is a predictor of mortality in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2021)

Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2020)

Intra-study and inter-technique validation of cardiovascular magnetic resonance imaging derived left atrial ejection fraction as a prognostic biomarker in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2020)

Fibroblast‐growth‐factor‐23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes
por: Kanagala, Prathap, et al.
Publicado: (2020)

Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction – implications for clinical trials
por: Kanagala, Prathap, et al.
Publicado: (2018)

Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach
por: Kanagala, Prathap, et al.
Publicado: (2020)

The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction
por: Lau, Clement, et al.
Publicado: (2022)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes
por: Gulsin, Gaurav S., et al.
Publicado: (2019)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
por: Voors, Adriaan A., et al.
Publicado: (2020)

Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study
por: Kanagala, Prathap, et al.
Publicado: (2019)

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
por: Cooper, Trond J., et al.
Publicado: (2022)

Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction
por: Sinha, Aish, et al.
Publicado: (2021)

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management
por: Kanagala, Prathap, et al.
Publicado: (2020)

Multi-modality assessment and role of left atrial function as an imaging biomarker in cardiovascular disease
por: Alfuhied, Aseel, et al.
Publicado: (2021)

The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction
por: Weerts, Jerremy, et al.
Publicado: (2022)

Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
por: Budde, Heidi, et al.
Publicado: (2022)

Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction
por: Giamouzis, Gregory, et al.
Publicado: (2016)

Estrogen Contributions to Microvascular Dysfunction Evolving to Heart Failure With Preserved Ejection Fraction
por: Sickinghe, Ariane A., et al.
Publicado: (2019)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Heart Failure with Preserved Ejection Fraction – Concept, Pathophysiology, Diagnosis and Challenges for Treatment
por: Miljkovik, Lidija Veterovska, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9gu0e8aueiq8j0s4o5119l9ik4